• OMNI Medical

Study: What is Cannabis Use Disorder and CBD Pharmacology

A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial by the Clinical Psychopharmacology Unit (University College London, London, UK) reports on Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial



Summary The trial by the Clinical Psychopharmacology Unit focused on “cannabis use disorder” and treatments of 400mg and 800mg of CBD for relief.


“substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. Therefore, we aimed to identify efficacious doses and eliminate inefficacious doses in a phase 2a trial using an adaptive Bayesian design.” States the Clinical Psychopharmacology Unit

Methodology of CBD THC Study


The trial by the Clinical Psychopharmacology Unit used medical industry standards for the CBD study.